175 related articles for article (PubMed ID: 24589668)
1. Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.
Coleman HG; Bhat SK; Murray LJ; McManus DT; O'Neill OM; Gavin AT; Johnston BT
Am J Gastroenterol; 2014 Apr; 109(4):527-34. PubMed ID: 24589668
[TBL] [Abstract][Full Text] [Related]
2. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
3. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
4. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
6. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
7. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
Bhat S; Coleman HG; Yousef F; Johnston BT; McManus DT; Gavin AT; Murray LJ
J Natl Cancer Inst; 2011 Jul; 103(13):1049-57. PubMed ID: 21680910
[TBL] [Abstract][Full Text] [Related]
9. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
11. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
Rugge M; Zaninotto G; Parente P; Zanatta L; Cavallin F; Germanà B; Macrì E; Galliani E; Iuzzolino P; Ferrara F; Marin R; Nisi E; Iaderosa G; Deboni M; Bellumat A; Valiante F; Florea G; Della Libera D; Benini M; Bortesi L; Meggio A; Zorzi MG; Depretis G; Miori G; Morelli L; Cataudella G; d'Amore ES; Franceschetti I; Bozzola L; Paternello E; Antonini C; Di Mario F; Dal Bò N; Furlanetto A; Norberto L; Polese L; Iommarini S; Farinati F; Battaglia G; Diamantis G; Realdon S; Guido E; Mastropaolo G; Canova D; Guerini A; Franceschi M; Zirillo M
Ann Surg; 2012 Nov; 256(5):788-94; discussion 794-5. PubMed ID: 23095623
[TBL] [Abstract][Full Text] [Related]
12. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
13. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
14. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
[TBL] [Abstract][Full Text] [Related]
15. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
17. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
18. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
[TBL] [Abstract][Full Text] [Related]
19. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
